Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab

To compare outcomes in patients with human epidermal growth factor receptor-2 (HER2)-positive breast cancer who received either dose-dense neoadjuvant chemotherapy (NAC) with trastuzumab or standard-interval chemotherapy with trastuzumab. Patients with HER2-positive breast cancer who received NAC, i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lize, Zhang, Yang, He, Yingjian, Li, Jinfeng, Wang, Tianfeng, Xie, Yuntao, Fan, Zhaoqing, Ouyang, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8196206/
https://www.ncbi.nlm.nih.gov/pubmed/34117262
http://dx.doi.org/10.1038/s41523-021-00284-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8196206/
https://www.ncbi.nlm.nih.gov/pubmed/34117262
http://dx.doi.org/10.1038/s41523-021-00284-y

Ejemplares similares